Vanguard Group Inc. Raises Position in Thermo Fisher Scientific Inc. $TMO

Vanguard Group Inc. lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.9% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 33,789,164 shares of the medical research company’s stock after buying an additional 309,207 shares during the period. Vanguard Group Inc. owned approximately 0.09% of Thermo Fisher Scientific worth $13,700,154,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Flossbach Von Storch SE grew its stake in shares of Thermo Fisher Scientific by 93.0% in the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock worth $1,105,698,000 after acquiring an additional 1,314,182 shares in the last quarter. Nuveen LLC bought a new stake in Thermo Fisher Scientific in the 1st quarter worth about $532,360,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Thermo Fisher Scientific by 29.5% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,257,424 shares of the medical research company’s stock valued at $915,295,000 after buying an additional 514,399 shares during the last quarter. EdgePoint Investment Group Inc. purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $172,139,000. Finally, Lindsell Train Ltd grew its holdings in shares of Thermo Fisher Scientific by 68.0% in the second quarter. Lindsell Train Ltd now owns 854,612 shares of the medical research company’s stock valued at $346,511,000 after acquiring an additional 345,822 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on TMO. Leerink Partners boosted their price objective on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. Raymond James Financial reaffirmed an “outperform” rating and set a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. JPMorgan Chase & Co. upped their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. UBS Group boosted their price target on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research report on Thursday, October 23rd. Finally, Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, October 8th. Nineteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $601.65.

Insiders Place Their Bets

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the completion of the sale, the executive vice president owned 21,152 shares of the company’s stock, valued at $12,144,420.80. The trade was a 1.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 52,140 shares of company stock valued at $29,104,464 over the last three months. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Down 1.9%

Shares of TMO stock opened at $567.49 on Tuesday. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The firm has a market cap of $213.21 billion, a P/E ratio of 32.78, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. The business has a 50-day moving average price of $529.51 and a two-hundred day moving average price of $469.36. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same period last year, the firm posted $5.28 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Thermo Fisher Scientific announced that its Board of Directors has authorized a stock buyback plan on Thursday, November 6th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to buy up to 2.4% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.